Skip to main content
OpenTrials
Completed

NCT Number: NCT03294720

BioACL Reconstruction With Amnion Collagen Matrix Wrap and Stem Cells Case Series

The objective of this study is to evaluate the use of wrapping an ACL graft with a collagen matrix tissue wrap and injecting autologous bone marrow aspirate concentrate under the wrapping and into the graft. Investigators hypothesize that this method of augmenting ACL surgery will accelerate and improve the graft maturation and ligamentization process. Investigators propose to test this hypothesis with a series of cases of ACL reconstructions evaluated with post-operative MRI mapping sequences and validated clinical outcome measures

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Andrews Institute

Gulf Breeze, Florida, 32561, United States

About this study

Histologic studies have determined that graft ligamentization following anterior cruciate ligament (ACL) reconstruction may take from 6 to 18 months. (1) It has been reported that incomplete graft maturation and incorporation is one cause of clinical graft failure. Animal studies have illustrated improved tendon healing/integration in ACL models augmented with stem cell technologies. (2-4). Basic scientists theorize that optimization of stem cell treatments for tissue regeneration requires that a "regenerative triad" be employed, i.e., use of a scaffold, stem cells and growth factors. In the intra-articular environment, research has shown that a scaffold such as an amnion wrap is necessary to contain the stem cells and growth factors in close proximity to the ACL graft. (2, 4, 5) The normal, uninjured human ACL is covered by a layer of synovial tissue which contributes to the blood supply and nutrition of the native ACL. It is theorized that the lack of a synovial lining after injury and following traditional ACL reconstruction contributes to slow ligamentization and possible failure of reconstructed grafts.(5) Two studies have demonstrated accelerated maturation and ligamentization of human ACL graft augmented with point of care blood products. (6, 7) In one, leucocyte poor platelet rich plasma was injected directly into the body of the graft. (6) In the other, the platelet derived growth factors were loaded in a gelatin carrier which was wrapped around the graft. (7) In both studies accelerated and increased ligament maturation was documented compared to the controls. Collagen membranes derived from amniotic tissue have been successful to aid healing when used in difficult wounds and meniscal repair surgery. (8, 9) Investigators believe that use of a collagen based -membrane derived from amniotic tissue can be used to help reestablish the natural synovial lining of the reconstructed ACL, in effect acting as both a barrier from the synovial fluid and as a scaffold to contain autologous mesenchymal stem cells and growth factors contiguous with the graft, thus aiding and perhaps accelerating the natural maturation and ligamentization process of the implanted graft tissue. Acceleration and improvement in graft maturation and strength would be a significant advancement in sports medicine allowing safer and earlier return to sports and activity.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients between the ages of 18 and 35 who are scheduled to have anterior cruciate ligament reconstruction with autologous grafts by the principal investigator will be screened for participation in this study.
  • Patients must be willing to undergo MRI scans post -operatively at 3, 6, 9 months and 1 year.

Exclusion criteria

  • Patients with prior procedures or significant prior injuries to the same knee are excluded. Any patient who will have difficulty obtaining internet access, does not have an active e-mail address, or is unable to comprehend study documents or give informed consent will be excluded.
  • Patient who are unable to complete MRI examinations due to claustrophobia or anxiety will be excluded.

Treatment and study plan

Bio-ACL

Procedure

ACL reconstruction with either hamstring or patellar autograft, wrapped in amion collagen wrap, and stem cells from bone marrow aspirate.

amnion wrap and BMAC

Device

amnion collagen wrap and bone-marrow aspirate in ACL reconstruction autograft

Primary outcomes

  1. MRI graft maturation and integration

    Time frame: 3 months, 6 months, 9 months, and 12 months post-op

    validated T2 star sequence which will undergo region of interest mapping to produce mean T2 values. These values have been shown to detect differences in ACL content, structure and maturation.

Secondary outcomes

  1. Changes in patient-reported pain rating

    Time frame: 3 months, 6 months, 9 months, 12 months post-op

    Visual analog scale will be used to assess pain

  2. Changes in Knee injury and Osteoarthritis Outcome Score (KOOS)

    Time frame: 3 months, 6 months, 9 months, 12 months post-op

    Patients will complete KOOS questionnaire on SOS

  3. Changes in Short Form 12 (SF-12) patient ratings

    Time frame: 3 months, 6 months, 9 months, 12 months post-op

    Patients will complete SF-12 questionnaire on SOS

  4. Changes in Single Assessment Numerical Evaluation (SANE) patient ratings for function

    Time frame: 3 months, 6 months, 9 months, 12 months post-op

    Patients will complete the SANE questionnaire on SOS

  5. Marx Activity Scale Rating

    Time frame: 3 months, 6 months, 9 months, 12 months post-op

    Patients will complete the Marx Activity questionnaire on SOS

Sponsors and collaborators

Lead sponsor

Andrews Research & Education Foundation

Other

Collaborators

  • Arthrex, Inc.

Registry information

Official study title

Augmentation of ACL Reconstruction With Bone Marrow Stem Cells and Amnion Collagen Matrix Wrap: a Case Series

Acronym: BioACL(CS)

Important dates

Study start
2018
Primary completion
2022
Study completion
2022
First posted
Sep 27, 2017
Registry last updated
Feb 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.